Healio

FDA approves three new pediatric indications for once-weekly growth hormone injection

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Healthline

Treatment Options for Growth Hormone Deficiency in Children

Pediatric growth hormone deficiency (PGHD) is a genetic condition that affects your child’s physical development. Hormone replacement therapy can help promote growth, and a new injection now makes it ...
Reuters

More evidence hormone therapy can muddy mammograms

NEW YORK (Reuters Health) - Hormone replacement therapy after menopause may interfere with the accuracy of mammograms used to screen for breast cancer -- and the risk may be greater with hormones ...
Rheumatology Advisor

No Increase in Mortality Risk with Menopausal Hormone Therapy, Researchers Report

Women taking menopausal hormone therapy do not face an increased risk of mortality, regardless of how long they take it, according to research published in The BMJ. In fact, women who undergo ...

Estrogen patches in short supply as demand for menopause hormone therapy grows

For many women in the United States who encounter drenching night sweats, sudden hot flashes, debilitating exhaustion and ...
WJFW

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for ...